![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
Preview |
PDF (Supplementary Information)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
477kB |
| Item Type: | Review |
|---|---|
| Title: | Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment - a systematic review and network meta-analysis |
| Creators Name: | Köhler, Michael, Paul, Friedemann, Janke, Kirsten, Sturtz, Sibylle, Preukschat, Daniela, Ostlender, Sabine, Kerekes, Michaela Florina and Kaiser, Thomas |
| Abstract: | BACKGROUND: Comparative assessments of all available disease-modifying therapies (DMTs) in patients with highly active relapsing-remitting multiple sclerosis (RRMS) are lacking, even though some of these DMTs are restricted to this MS subpopulation. We therefore aimed to compare DMTs in patients with highly active RRMS using re-analyses of individual patient data (IPD) provided by study sponsors. METHODS: We searched for randomised controlled trials (RCTs) that included adult patients with RRMS and directly compared alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab, ofatumumab, ozanimod, ponesimod and teriflunomide, or compared these DMTs with other drugs or placebo. Re-analyses of IPD for subpopulations of patients with high disease activity despite previous DMT were included in network meta-analyses (NMAs). As there is no widely accepted definition of high disease activity in RRMS, criteria were chosen to cover as wide a range of definitions as possible, while being sufficiently similar across studies. RESULTS: We identified 14 relevant RCTs, including only 3 head-to-head comparisons of DMTs, and no relevant studies on natalizumab. All studies were pivotal studies for approval. The available re-analyses of IPD did not allow comprehensive NMAs. The main reasons for this were the overall paucity of RCTs, especially head-to-head comparisons, and a high risk of bias. In addition, data on patient-relevant outcomes and long-term follow-up (> 2 years) were lacking. CONCLUSION: Based on the largest possible evidence base, including previously unpublished data, our systematic review shows substantial evidence gaps for DMTs in highly active RRMS. This indicates a need for further research beyond regulatory requirements. |
| Keywords: | Multiple Sclerosis, High Disease Activity, Data Availability, Systematic Review |
| Source: | BMC Neurology |
| ISSN: | 1471-2377 |
| Publisher: | BioMed Central |
| Volume: | 25 |
| Number: | 1 |
| Page Range: | 328 |
| Date: | 9 August 2025 |
| Official Publication: | https://doi.org/10.1186/s12883-025-04338-7 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
